Biomarkers and translational studies at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

24 organizations at ENA 2026 present work in biomarker assays and translational studies: 7 drug developers, 7 universities and institutes, 6 cancer centres and hospitals and 4 CROs and suppliers. Between them they bring 49 presentations to the program. Most represented: MD Anderson Cancer Center, Arcus Biosciences and NEXT Oncology. As of Oct 13, 2026.

All 254 organizations at ENA 2026 →

Showing 1–11 of 24 organizations

Organization	ENA 2026 Attendance
MD Anderson Cancer Center Houston, Texas
mdanderson.org Cancer centres & hospitals University of Texas cancer centre for patient care, research and early-phase clinical trials.	Session Wed Nov 18 4:15–5:45pm Workshop 2: Radiopharmaceuticals ADCs & radioligands Talk Wed Nov 18 4:55–5:15pm Part of Workshop 2: Radiopharmaceuticals Translating Radiopharmaceutical Innovation from Bench to Bedside ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Translational validation of uPARAP (MRC2) as an antibody–drug conjugate target in osteosarcoma patient-derived xenograft models ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Preliminary phase 1 results from AVENTINE-1, a phase 1/2 study of AVZO-1418, an EGFR-HER3 bispecific antibody-drug conjugate (BsADC) for the treatment of patients with locally advanced or metastatic solid tumors ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Population pharmacokinetics (popPK) and exposure-response analyses of sacituzumab tirumotecan (sac-TMT) antibody-drug conjugate (ADC) in participants (pts) with advanced solid tumors ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers TROP2 Predicts Response to TUSC2 Gene Therapy (Quaratusugene Ozeplasmid) and Its Modulation Sensitizes Non-Small Cell Lung Cancer to Treatment Targeted agents Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies Targeting the PI4K2A lysosomal pathway is a promising approach for lung cancer therapy Biomarkers Talk Thu Nov 19 10–10:10am Part of Plenary Session 3: Proffered Papers Phase 1 trial and translational study of the glutaminase-1 (GLS1) inhibitor IACS-6274 in combination with bevacizumab and paclitaxel in patients with advanced ovarian cancer Early clinical · Targeted agents Session Thu Nov 19 2–2:30pm Posters in the Spotlight, session 1 Session Thu Nov 19 3–4:30pm Workshop 3: End-to-End Early Clinical Development Through AI AI · Early clinical Session Thu Nov 19 3–4:30pm Workshop 4: Next-Generation Precision Oncology: Progress, Pitfalls and Promise Genomics Talk Thu Nov 19 3:20–3:40pm Part of Workshop 3: End-to-End Early Clinical Development Through AI Radiology - Digital twins and multiomics AI · Early clinical Talk Thu Nov 19 3:40–4pm Part of Workshop 4: Next-Generation Precision Oncology: Progress, Pitfalls and Promise Rewiring the Cell Cycle: Early Clinical Insights from Next-Generation Cyclin and CDK Targeting Genomics Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Drug Delivery A Bayesian pharmacokinetics-integrated Phase I–II design to optimize dose-schedule regimes Drug design Talk Fri Nov 20 3–3:10pm Part of Plenary Session 7: Proffered papers Interim results from the ﬁrst-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051) Early clinical · Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Combination Therapies Discovery of novel combination strategies to target SWI/SNF mutant lung cancers Targeted agents
Arcus Biosciences Hayward, CA
arcusbio.com Biotech Develops cancer medicines including the HIF-2 alpha inhibitor casdatifan and immunotherapy combinations.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers Selective targeting of AXL overcomes inherent resistance to RAS targeting therapies Targeted agents Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies A HIF-2α activity signature highlights the therapeutic potential of casdatifan as an HCC treatment Biomarkers Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Hypoxia-inducible factor-2α inhibition with casdatifan combines with checkpoint receptor modulation to enhance tumor control Targeted agents
NEXT Oncology San Antonio, Texas
nextoncology.com Cancer centres & hospitals Network of phase 1 cancer clinical trial sites in the US, Spain and other countries.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates First Results from a First-in-Human Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502, an anti-Nectin-4 ADC, as a Single Agent in Advanced Solid Tumors ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies Lineage- and allele-specific coupling of KRAS alterations with NF-kB inflammatory pathway activity in solid tumours Biomarkers Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Novel clinical trial design A First-in-Human Phase 1/2 Study of SAR449336, an Oral Non-Covalent Pan-KRAS Inhibitor, in Patients With Advanced KRAS-Mutant Solid Tumors (Trial in Progress) Early clinical
Immuneering Cambridge, Massachusetts
immuneering.com Biotech Clinical-stage oncology company developing atebimetinib, a deep cyclic MEK inhibitor for MAPK-driven cancers.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies Atebimetinib, a deep cyclic inhibitor of MEK, combined with chemotherapy: preclinical rationale for treatment of anaplastic thyroid cancer (ATC) Biomarkers Talk Thu Nov 19 2:20–2:25pm Part of Posters in the Spotlight, session 1 Patient-aligned 3D tumor models identify biomarker-enriched atebimetinib (IMM-1-104) combination strategies in pancreatic ductal adenocarcinoma Preclinical models · Targeted agents
IRCCS Istituto Giannina Gaslini Genoa, Italy
gaslini.org Cancer centres & hospitals Paediatric research hospital, including paediatric oncology and neuroblastoma research.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Biomarkers Assays Neuroblastoma differentiation is accompanied by dynamic nucleolin redistribution Biomarkers Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Drug Delivery Microfluidic-Assisted Preparation of PLGA Nanoparticles for Neuroblastoma Applications Drug design
Urosphere Toulouse, France
urosphere.com CROs & CDMOs Preclinical contract research company offering urology and oncology models, including patient-derived xenografts and organoids.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies Patient-derived PDX and organoid models reveal distinct molecular mechanisms of acquired resistance to olaparib and enfortumab vedotin in genitourinary cancers Biomarkers Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models Matched Patient-Derived Xenografts and Organoids Faithfully Preserve the Molecular Landscape and Drug Response of Breast Cancer Preclinical models
Bantam Pharmaceutical Durham, NC
bantampharma.com Biotech Clinical-stage company developing oral small molecules, including BTM-3566, that kill cancer cells by targeting mitochondrial dynamics.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Biomarkers Assays Biomarker-signature determinants of BTM-class OMA1-activator sensitivity in solid tumor cell lines, with prevalence mapped in 9,850 human tumors Biomarkers Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs Intermittent BTM-3566 in advanced solid tumors: initial safety and pharmacokinetics Drug design
IRBM Pomezia, Italy
irbm.com CROs & CDMOs Contract drug discovery company offering medicinal chemistry, biology and preclinical services.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies Transcriptomic profiling defines responders to brain-penetrant SHP2 inhibition in glioblastoma Biomarkers Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models C3PO: Complex 3D Patient Organoids for Preclinical Drug Testing in Brain Tumors Preclinical models
John Paul II Catholic University of Lublin Lublin, Poland
kul.pl Universities & institutes Catholic university in Lublin, Poland, with faculties spanning the humanities, social sciences and natural sciences.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Biomarkers Assays Evaluation of MAGE (melibiose-derived advanced glycation end-product) and HER2 in Peritoneal Lavage Fluid and Blood as Potential Biomarkers of Treatment Response in Gastric Cancer Biomarkers Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Tumour immunology and inflammation Stimulatory effect of the whole bovine thymus extract and isolated fractions on model monocytes, macrophages, dendritic, and cancer cells in vitro Immuno-oncology
Actuate Therapeutics Fort Worth, TX
actuatetherapeutics.com Biotech Clinical-stage company developing elraglusib, a GSK-3 beta inhibitor, for pancreatic and other cancers.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies Evaluation of antitumor activity of oral elraglusib in B16F10 melanoma model Biomarkers
Auburn University Auburn, AL
	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies A comparative translational framework identifies conserved biomarkers and molecular pathways in metastatic osteosarcoma Biomarkers